Now that knowing your DNA/PharmacoGenetics is key to a lifetime benefit, see the Best Practices Solution, while making some additional dollars in reimbursement revenues.

1. Solutions for PharmacoGenetic Testing
AB Consulting for Healthcare- 4541 N.64th St., Scottsdale, AZ 85251 (480)399-2877
abenson54@msn.com
The benefits of PGx America, bringing an
additional “Best Practices” Solution to your practice, are multifaceted. Because PGxA has a
“billing guru” on staff, who settles in with your billers, they find everything there is to
legitimately find and realize a significant enhancement to a practices' regular fee
slip/patient. Even if you are leaving as little as $25/$35/patient, and in most instances out
of the Medicaid arena is $75/patient in enhancements. The additional benefits to your
practice, from a dollar standpoint is one discussion, the other points are when we look to
the three real reasons to administer PGx tests to your patients; The Medicine,The Money &
The Marketing. If we stipulate that $25/$35 per patient with over 200/300 tests being
performed per month is not motivating enough, then we are left with the best reason to
fully utilize genetic testing, the Medicine.
Your population is mostly, if not completely, medication dependent with high cross co-
morbidities of pain and depression. Those patients who are hyper-metabolizing certain
meds, including codeine, are very likely to be labeled as “drug abusers,” when in fact, they
are not realizing the necessary relief in order to live a stable, satisfying life. Those who are
very low metabolizers are also at a greater risk of adverse drug reactions, including
death. The availability of this test, at “No Cost” to the patient, makes it a necessity to be
included with the full treatment of your entire patient panel. Incoming outcomes mandates
and legal liabilities also need to be considered.
We feel confident we can bring more revenue to the clinic, but never want to lose
perspective on why we do what we do. Please take a look at the link below for additional
findings: http://www.pgxam.com/pgx-across-america.html
CONCLUSIONS:
Adoption of PharmacoGenetic tests in routine clinical practice has been sparse. One major barrier to
clinical implementation is the lack of clear, curated, peer-reviewed PharmacoGenetic guidelines. CPIC
guidelines represent a critical step enabling the translation of clinical genetic test results into actionable
prescribing decisions. All CPIC guidelines adhere to a standard format and contain the necessary
information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes
or drug prescribing groups.
Our experiences indicate that key factors for successful development and adoption of these guidelines
include: (1) adhering to standard systems for grading levels of evidence and for assigning strength to
each prescribing recommendation; (2) close collaboration among clinicians, scientists, pharmacologists,
and informatics experts; (3) provision of clear and specific recommendations for prescribing and (4)
converting the guidelines into machine readable formats for incorporation into electronic medical
records and linking to clinical decision support tools. The underlying principle, that CPIC guidelines
provide recommendations on how to use but not whether to order genetic tests, has allowed the
guideline development process to focus on practical aspects of implementing pharmacogenomics into
clinical care. Let PGx America do a free analysis of your practice today!